InspireMD, Inc. — Form 8-K
Filed August 17, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 68/100
What the filing says
InspireMD reported Q2 2026 revenue of $1.8M (flat vs. Q2 2025), but U.S. operations posted a negative $351K due to a voluntary May 2026 recall of the CGuard Prime 135 cm delivery system, which generated $734K in customer credits and $612K inventory impairment. The company hired Kathleen Kennedy as SVP Global Sales & Marketing, commenced CGUARDIANS III trials, and initiated post-quarter cost-reduction actions targeting $9M annual savings. Cash declined 44% to $30.4M (from $54.2M year-end 2025); H1 2026 net loss was $28M. FDA decisions on CGuard Prime 80 cm (TCAR) and original CGuard (CAS) expected later in 2026.
Why this rating
Recall and $1.4M combined charges are ~2.3% of market cap; $9M cost cuts significant relative to $28M H1 loss. Cash burn and going-concern risk material; regulatory delays and market re-entry uncertain.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.